<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878614</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#20-002097</org_study_id>
    <nct_id>NCT04878614</nct_id>
  </id_info>
  <brief_title>Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding</brief_title>
  <official_title>Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a liquid levothyroxine formula and examine if it will&#xD;
      lead to improvement in management of thyroid function and if it improves hypothyroid symptoms&#xD;
      that patients experience.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who require enteral nutrition through an enteral feeding tube and have&#xD;
      hypothyroidism often struggle with the management of hypothyroidism. Hypothyroidism usually&#xD;
      requires lifelong treatment except in some cases. It has been clinically observed the&#xD;
      traditional management of hypothyroidism is to crush the tablet and administer the medical&#xD;
      through the enteral nutrition tube and hold the feeds for one hour. However, management of&#xD;
      the hormonal profile has been noted to have variable results with this method. Limited data&#xD;
      is available about the effectiveness of levothyroxine liquid formulation in outpatients'&#xD;
      dependent on enteral feeding tubes for administration.&#xD;
&#xD;
      Therefore, we propose a study to assess if daily treatment of, Tirosint-SOL (liquid&#xD;
      levothyroxine, IBSA pharma Inc.), will improve thyroid function tests in individuals&#xD;
      requiring enteral nutrition and are hypothyroid in a prospective, randomized study in a&#xD;
      population requiring enteral nutrition. We hypothesize that Tirosint-SOL will lead to&#xD;
      improvement in management in their thyroid function tests resulting in possible improvement&#xD;
      in hypothyroid symptoms experienced by the patients.&#xD;
&#xD;
      This will be a randomized controlled trial. The study will be conducted in patients who have&#xD;
      uncontrolled hypothyroidism on levothyroxine therapy. These patients will also be dependent&#xD;
      on enteral nutrition and medication administration through the gastrostomy tube. The&#xD;
      participants will be followed at UCLA Enteral Nutrition Clinic. Participants will be&#xD;
      randomized 1:1 to either continue current management with the same dose or to dose equivalent&#xD;
      liquid levothyroxine. At baseline (week 0) and week 6-8, TSH and thyroid function tests will&#xD;
      be performed. In addition, medical history and physical, body weight, HR, blood pressure,&#xD;
      nutritional intake by a registered dietitian will be done at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This will be a randomized controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participants will be randomized 1:1 to either continue current management with the same dose or to dose equivalent liquid levothyroxine</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change of TSH</measure>
    <time_frame>6 weeks</time_frame>
    <description>evaluate change in thyroid hormonal panel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with therapeutic FT4</measure>
    <time_frame>6 weeks</time_frame>
    <description>evaluate change in thyroid hormonal panel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with therapeutic FT3</measure>
    <time_frame>6 weeks</time_frame>
    <description>evaluate change in thyroid hormonal panel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Standard Levothyroxine Management</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will continue with the same regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid Levothyroxine Management</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with dose equivalent regimen through enteral feeding tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Tablet</intervention_name>
    <description>Standard clinical management</description>
    <arm_group_label>Standard Levothyroxine Management</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levothyroxine Sodium</intervention_name>
    <description>Liquid levothyroxine through enteral feeding tube</description>
    <arm_group_label>Liquid Levothyroxine Management</arm_group_label>
    <other_name>Tirosint-SOL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults age 18 years old or older&#xD;
&#xD;
          -  G-tube/G-J tube dependent for medication administration&#xD;
&#xD;
          -  Hypothyroid patients on levothyroxine tablet&#xD;
&#xD;
          -  TSH&gt;5 on levothyroxine&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  J-tube&#xD;
&#xD;
          -  Unstable cardiac condition&#xD;
&#xD;
          -  Unstable gastrointestinal condition&#xD;
&#xD;
          -  Unable to reliably administer medication&#xD;
&#xD;
          -  Screening laboratory value outside of the laboratory normal range that is considered&#xD;
             clinically significant for study participation by the investigator.&#xD;
&#xD;
          -  In the opinion of the study investigator, any subject who demonstrate a risk of&#xD;
             non-compliance with study procedure, or one who cannot read, understand or complete&#xD;
             study - related materials.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijiya Surampudi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vijiya D Surampudi, MD</last_name>
    <phone>310-206-1987</phone>
    <email>vsurampudi@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeraldine Guzman, BS</last_name>
    <phone>310-206-8292</phone>
    <email>jbguzman@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Center for Human Nutrition</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijiya Surampudi, MD</last_name>
      <phone>310-206-1987</phone>
      <email>vsurampudi@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeraldine B Guzman, BS</last_name>
      <phone>310-206-8292</phone>
      <email>jbguzman@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Vijiya Surampudi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>May 4, 2021</last_update_submitted>
  <last_update_submitted_qc>May 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Vijaya Surampudi MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Levothyroxine</keyword>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Gastrostomy Tube</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

